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Objectives:  In  patients  with  advanced  incurable  lung cancer  deciding  as  to  the most  appropriate  treatment
(e.g.  chemotherapy  or supportive  care  only)  is  challenging.  In  such  patients  the  TNM  classiﬁcation  system
has reached  its  ceiling  therefore  other  factors  are  used  to  assess  prognosis  and  as  such,  guide  treatment.
Performance  status  (PS),  weight  loss  and  inﬂammatory  biomarkers  (Glasgow  Prognostic  Score  (mGPS))
predict  survival  in advanced  lung  cancer  however  these  have  not  been  compared.  This  study  compares
key  prognostic  factors  in advanced  lung cancer.
Materials and  methods:  Patients  with  newly  diagnosed  advanced  lung  cancer  were  recruited  and  demo-
graphics,  weight  loss,  other  prognostic  factors  (mGPS,  PS)  were  collected.  Kaplan–Meier  and  Cox
regression  methods  were  used  to  compare  these  prognostic  factors.
Results:  390  patients  with  advanced  incurable  lung  cancer  were  recruited;  341  were  male,  median  age
was  66  years  (IQR 59–73)  and  patients  had  stage  IV  non-small  cell  (n = 288)  (73.8%)  or extensive  stage
small  cell  lung cancer  (n = 102)  (26.2%).  The  median  survival  was  7.8 months.  On  multivariate  analysis
only  performance  status  (HR  1.74 CI 1.50–2.02)  and  mGPS  (HR 1.67,  CI  1.40–2.00)  predicted  survival
(p <  0.001).  Survival  at 3  months  ranged  from  99%  (ECOG  0–1)  to 74%  (ECOG  2) and  using  mGPS,  from  99%
(mGPS0)  to  71%  (mGPS2).  In  combination,  survival  ranged  from  99%  (mGPS  0,  ECOG  0–1)  to 33% (mGPS2,
ECOG  3).
Conclusion:  Performance  status  and  the  mGPS  are  superior  prognostic  factors  in  advanced  lung  cancer.
In  combination,  these  improved  survival  prediction  compared  with  either  alone.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
In most patients that present with advanced lung cancer (stage
II–IV), there are the options of oncology treatment (including
hemotherapy, radiotherapy, targeted therapy) or best supportive
are (palliative care) alone [1]. The beneﬁts of any treatment must
e balanced with the side-effects, which in cancer treatment often
re considerable.
∗ Corresponding author at: Edinburgh Cancer Centre, Western General Hospital,
rewe Road, Edinburgh, UK. Tel.: +44 7766503469; fax: +44 131 777 3564.
E-mail address: barry.laird@ed.ac.uk (B.J. Laird).
1 Joint senior authors.
ttp://dx.doi.org/10.1016/j.lungcan.2015.03.020
169-5002/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A fundamental factor inﬂuencing treatment decisions in
advanced lung cancer is the expected prognosis, however clini-
cians are often inaccurate in survival predictions, and can have a
tendency to overestimate the prognosis [2]. There are currently no
good predictors of the beneﬁt of chemotherapy; however prognosis
is currently being used to select those who receive chemotherapy.
The most established factor for assessing prognosis is performance
status and this is advised in guidelines for lung cancer treatment
[3]. Furthermore, studies have shown that many patients receive
inappropriate anti-cancer treatment near the end of life [4]. Bet-
ter prognostic tools are needed to avoid unnecessary, potentially
harmful therapy during end of life.
In addition to performance status, various other factors have
been shown to independently predict survival in advanced lung
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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weight loss (%) in the previous 3 months (p = 0.001), performance
status (p < 0.001) and mGPS (p < 0.001) were signiﬁcant predic-
tors of survival. On multivariate analysis only performance status
(p < 0.001) and mGPS (p < 0.001) were predictors of survival.
Table 1
Patient demographics (n = 390).
Parameter n % Median (IQR)
Sex (M/F) 341/49 87.4/12.6
Tumor type
Non-small cell lung
Small cell lung
288
102
73.8
26.2
Age (≤65/65–74/≥74
years)
154/150/86 39.5/38.5/22.1 66.0 (59.0–73.0)
Survival (months) 7.8 (3.5–13.6)
Weight loss in past 3
months
294 75.3 5.04 (0.8–10.2)
Weight loss category
in past 3 months
(%)
Weight loss < 5.0%
Weight loss > 5.1%
(cancer cachexiaa)
195
195
50.0
50.0
BMI (kg/m2) 25.2 (22.5–28.5)C.P. Simmons et al. / Lun
ancer, such as weight loss and systemic inﬂammation. Weight
oss is common in patients presenting with lung cancer and typ-
cally worsens as disease progresses, with around 60% of patients
eporting signiﬁcant weight loss in their last few months of life
5]. Studies have also linked weight loss in lung cancer to reduced
urvival, independent of treatment received. Furthermore, patients
ith weight loss are less likely to complete their intended course
f chemotherapy and are more likely to experience chemotoxic-
ty than patients without weight loss, independent of tumor status
5]. Weight loss in patients with lung cancer is therefore of symp-
omatic, predictive and prognostic relevance.
Measures of the systemic inﬂammatory response are of
ndependent prognostic value in cancer. A combination of the
nﬂammatory markers CRP (C-reactive protein) and albumin (Alb)
ermed the modiﬁed Glasgow Prognostic Score (mGPS), has been
he most extensively studied and validated prognostic scoring tool.
he mGPS score has also been shown to correlate with weight loss
n patients with advanced cancer, and is associated with increased
reatment toxicity, reduced treatment response and poor nutri-
ional status [6–8].
Although weight loss, performance status and the mGPS have
een shown to be of independent prognostic value in lung cancer,
hey have not been compared with each other. Therefore the pri-
ary aim of the present study was to compare these prognostic
actors in patients with advanced lung cancer, to assess which has
he greatest prognostic value in order to guide treatment. A sec-
ndary aim was to assess if independent prognostic factors could
e combined to improve survival prediction.
. Materials and methods
A prospective observational study was conducted. Consecutive
atients were recruited from two University Hospitals in Greece:
he ﬁrst cohort was evaluated in the University Hospital of Her-
kleion between 6 February 2006 and 12 October 2010 (with
ollow-up until 27 October 2011) and the second in University Hos-
ital of Larissa between 30 March 2010 and 13 December 2013
with follow-up until 1 June 2013).
Eligible patients were 18 years of age or older, had advanced
ung cancer (stage IV NSCLC or extensive stage SCLC) and were due
o start systemic anti-cancer therapy.
The following data were collected: sex, age, cancer type, body
ass index (BMI), percentage weight loss in the preceding 3
onths, performance status, albumin, CRP, and survival status at
ollow-up.
Age, percentage weight loss in the preceding 3 months, perfor-
ance status, CRP and albumin were categorized using standard
hresholds to aid comparison and stratiﬁcation of results.
Performance status was measured according to the Eastern
ooperative Oncology Group (ECOG) classiﬁcation which ranges
rom grade 0 (fully active) to grade 5 (dead). ECOG grades 0 and 1
ere grouped into one category as this has been standard practice
n the majority of prospective phase III trials in lung cancer and sur-
ival changes dramatically in patients with PS2 versus PS0-1 [9,10].
ge was divided into patients less than 65 years of age, between
5 and 74 years and greater than 74 years of age. Cachexia was
eﬁned as >5% weight loss, in line with the international consensus
lassiﬁcation [11].
CRP and albumin values were used to calculate the mGPS score
or each patient. The limit of detection for CRP was 5 mg/L and all
amples were processed according to standardized laboratory pro-
edures. The mGPS was calculated as follows: CRP ≤ 10 mg/L = 0,
RP > 10 mg/L = 1, CRP > 10 mg/L and albumin < 35 g/L = 2.
Individuals’ demographic indices and categories were analyzed
nd compared to their survival status. Survival time was calculatedcer 88 (2015) 304–309 305
in months and deﬁned as the time from study entry until death,
or censored if alive at follow-up date. Survival curves were plotted
using Kaplan–Meier methods and the log-rank test was applied.
Survival analysis was performed using Cox proportional hazards
model and hazard ratios (HRs) were calculated. Multivariate sur-
vival analysis was conducted using a stepwise backward procedure
to derive a ﬁnal model of the variables that had a signiﬁcant inde-
pendent relationship with survival. Stratiﬁcation by primary cancer
site was  performed for the survival analysis. Factors that were pre-
dictive of survival in the multivariate analyses were ﬁnally grouped
together to assess whether they had better prognostic accuracy
when grouped together.
Statistical analysis was performed using SPSS version 19. All sta-
tistical testing was conducted at the 5% level, and 95% conﬁdence
intervals (CI) are reported throughout. Where n ≤ 10, these groups
were not reported.
The study has been conducted and adheres to the Reporting
Recommendations for Tumor Marker Prognostic Studies (REMARK)
guidelines [12].
3. Results
There were 390 patients included and their demographics are
detailed in Table 1. All patients had advanced incurable lung cancer
(stage IV NSCLC or extensive stage SCLC). The majority of patients
was male (n = 341, 87.4%) and the median age was  66 years (IQR
59–73). The median performance status was 1 (IQR 1–2). Median
survival was  7.8 months (IQR 3.5–13.6) reﬂecting the advanced dis-
ease staging of the population. The minimum and median follow-up
for survivors was 0.6 months and 12.8 months, respectively. At the
time of cessation of data collection, 107 patients were alive and 283
had died. Patients had either non-small cell lung cancer (n = 288)
(73.8%) or small cell lung cancer (n = 102) (26.2%).
The median weight loss in the previous three months was  5.0%
(IQR 0.8–10.2). The median BMI  was 25.2 (IQR 22.5–28.5).
Clinico-pathological factors and survival were compared for this
cohort of patients and are detailed in Table 2. On univariate sur-
vival analysis, age (p = 0.004), sex (p = 0.009), tumor type (p = 0.007),Performance status
(ECOG) (0–1/2/3/4)
1 (1–2)
SD, standard deviation; IQR, interquartile range.
a Deﬁned as weight loss >5%.
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Table 2
The relationship between clinic-pathological factors and survival in patients with metastatic lung cancer (n = 390).
Parameter n % Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Sex (M/F) 341/49 87.4/12.6 0.60 (0.41–0.88) 0.009
Age  (≤65/65–74/≥74 years) 154/150/86 39.5/38.5/22.1 1.28 (1.08–1.50) 0.004
Tumor type (NSCLC versus SCLC) 288/102 73.8/26.2 1.39 (1.10–1.77) 0.007
Weight loss (%) category in past 3 months (1/2)a 195/195 50.0/50.0 1.49 (1.18–1.88) 0.001
Performance status (ECOG) (0–1/2/3/4) 271/75/31/13 69.5/19.2/7.9/3.3 1.90 (1.65–2.18) <0.001 1.74 (1.50–2.02) <0.001
mGPS (0/1/2) 103/183/104 26.4/46.9/26.7 1.84 (1.54–2.19) <0.001 1.67 (1.40–2.00) <0.001
a Weight loss (%) category: 1 = weight loss <5%, 2 = weight loss >5.1% (cancer cachexia).
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WFig. 1. Weight loss is associated with reduced survival (log rank p = 0.001). The 
Figs. 1–3 show Kaplan–Meier survival curves for weight loss,
erformance status and mGPS respectively.
Table 3 shows the relationship between survival at 3 months andGPS and performance status. Survival was compared across all
ategories for both mGPS and performance status. For performance
tatus, survival at 3 months ranged from 99% (ECOG 0–1) to 74%
ECOG 2). For mGPS, survival at 3 months ranged from 99% (mGPS0)
able 3
he relationship between mGPS and performance status and the survival rate (%) at
 months in patients with metastatic lung cancer (n = 390).
Performance
status (ECOG
grouping)
mGPS 0 mGPS 1 mGPS 2 mGPS 0–2
0–1 99%
n = 79
95%
n = 133
71%
n = 59
91%
n = 271
2  74%
n = 19
71%
n = 34
59%
n = 22
68%
n = 75
3  n = 4 55%
n = 12
33%
n = 15
44%
n = 31
4  n = 1 n = 4 n = 8 23%
n = 13
0–4 92%
n = 103
87%
n = 183
58%
n = 104
81%
n = 390
here n < 10, analysis not performed.nder the receiver operator curve (ROC) was 0.49 (95% CI = 0.43–0.55), p = 0.661.
to 71% (mGPS2). When used in combination, survival at 3 months
ranged from 99% (mGPS 0 and ECOG 0–1) to 33% (mGPS = 2 and
ECOG 3). Performance status does correlate with mGPS (Pearson
coefﬁcient is 0.0206, p < 0.001) however this must be taken in the
context of the large sample size so limited inference can be drawn
from this.
4. Discussion
The results of this study show that age, sex, weight loss, tumor
type, performance status and markers of the systemic inﬂamma-
tory response (mGPS), all have prognostic value in patients with
advanced lung cancer. Performance status and the mGPS carry the
greatest prognostic value, however it is of interest that the mGPS
has strong prognostic accuracy and performs almost identically to
performance status. In addition, the combination of performance
status and mGPS points to a new method of prognosis in advanced
lung cancer.
Performance status (measured either by Karnofsky or ECOG
classiﬁcation) still remains the gold standard prognostic measure
and the results of the present study support this [13,14]. However,
the key limitation of performance status is that it is an entirely
subjective assessment of a patient’s physical activity and function-
ing [15–17]. It has been shown that marked discrepancies often
C.P. Simmons et al. / Lung Cancer 88 (2015) 304–309 307
Fig. 2. Decreasing performance status was associated with reduced survival (log-rank p < 0.001). The area under the ROC was 0.62 (95% CI = 0.56–0.68), p < 0.001.
Fig. 3. Increasing mGPS was  associated with reduced survival (log-rank p < 0.001). The area under the ROC was 0.61 (95% CI = 0.55–0.67), p = 0.001.
3 g Can
e
s
d
o
s
d
a
p
l
i
i
e
f
i
[
l
b
s
i
t
e
p
p
i
a
n
u
r
e
i
r
a
B
f
p
m
a
c
s
t
p
I
w
v
r
d
m
t
t
[
h
a
p
r
s
a
b
s
c
p
w
[
[
[08 C.P. Simmons et al. / Lun
xist between clinicians’ and patients’ assessments of performance
tatus [18]. Furthermore, clear inter-observer variability has been
emonstrated [19]. Therefore it is important that the limitations
f using a prognostic measure which is subjective and is variable,
uch as performance status, are considered. This aspect is of fun-
amental importance when the majority of treatment decisions in
dvanced lung cancer are deeply inﬂuenced by performance status.
In contrast, the mGPS has clear advantages. These ﬁndings sup-
ort that the mGPS has independent prognostic value in advanced
ung cancer, however a clear advantage over performance status
s that it is objective and has 100% inter-observer congruence. It
s simple to measure, inexpensive and is widely available. Used
ither in isolation or, perhaps even more, in combination with per-
ormance status, the present ﬁndings demonstrate its relevance in
ncreasing accuracy of survival prediction in metastatic lung cancer
20]. This has been shown in other cancer types [21].
The ﬁndings also suggest that the role of weight loss in advanced
ung cancer should be viewed with caution. Weight loss has long
een regarded a “poor” prognostic sign in lung cancer. This study
peciﬁcally reviewed weight loss greater than 5%. Cancer cachexia
s deﬁned as weight loss greater than 5% and felt by many to be
he most adverse weight related prognostic factor in cancer. How-
ver the ﬁndings suggest that the use of weight loss as an early,
rognostic factor in lung cancer is of considerably less value than
erformance status and mGPS and should not be assessed routinely
n the clinic. For this to happen it would mean a change of mind set,
s weight loss is a source of concern for patients, families and cli-
icians. It is regularly recorded at clinic appointments and may  be
sed as a trigger for more investigations (suspected disease recur-
ence/progression) and dietetic referral or as a starting point for
nd of life discussions. In addition, the conﬁrmation of weight loss
n cancer is often upsetting for patients/families and they need to
eceive information regarding how to manage this. The ﬁndings
lso demonstrate that cachexia (as per current deﬁnition) [11] and
MI  did not offer additional prognostic value in the presence of per-
ormance status and mGPS. However, if these factors have limited
rognostic, their relative value should be re-evaluated.
There is an urgency for improved survival prediction in
etastatic lung cancer. Recent work has demonstrated that
pproximately 10% of metastatic lung cancer patients receive anti-
ancer therapy in the last 30 days of life [22], and patients with the
hortest survival time after diagnosis received more anti-cancer
herapy near the end of life. A key consideration in deciding appro-
riate treatment in an advanced lung cancer patient is prognosis.
n these patients, the beneﬁts of anti-cancer therapy must be
eighed against potential disadvantages, such as multiple hospital
isits, side effects and potentially life-threatening toxicity. Accu-
ate assessment of prognosis is needed to inform such complex
ecisions between patients and clinicians.
The results of the present study show that the combination of
GPS and performance status are more accurate in survival predic-
ion than either in isolation. This has been shown in other cancer
ypes and has now been demonstrated in advanced lung cancer
21]. Using the combination of mGPS and performance status may
ave considerable application in considering treatment options in
dvanced lung cancer; for example when to use chemotherapy in
atients near the end of life. This approach has been supported in
ecent work which has shown the value of using the mGPS as a
tratiﬁcation factor in very advanced disease to reduce chemother-
py use [22]. The present study takes this approach one step further
y combining mGPS with performance status, to increase progno-
tic accuracy. This novel approach could then be used to guide the
hoice of oncology treatment in advanced lung cancer patients.
The present study has several limitations. There was a high
roportion of men  and SCLC in the cohort studied in keeping
ith the epidemiology of lung cancer in Greece. Furthermore not
[
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all previously studied prognostic factors in advanced NSCLC have
been examined. However as performance status remains the gold
standard prognostic measure in use clinically, its inclusion here is
important. Details on cancer treatment, EGFR mutations and histo-
logical subtype (for NSCLC) are not available and this would be of
interest to assess the effect of response of chemotherapy in patients
in poor prognostic groups. All patients in the study were due to start
anti-cancer therapy and therefore the number of patients with PS
3 or 4 was small.
5. Conclusion
Performance status and mGPS are superior prognostic factors in
metastatic lung cancer and in combination increase survival pre-
diction in advanced lung cancer. In translating this to clinical care,
these factors should now be examined in the setting of treatment
stratiﬁcation in the complex area of advanced lung cancer. Contin-
uing studies are eagerly awaited.
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